Skip to main content
OpenTrials
Completed

NCT Number: NCT04799353

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

This study will evaluate how safe Budigalimab is and how it moves within the body in adult participants with HIV-1 infection.

Budigalimab is an investigational drug being evaluated for the treatment of Human Immunodeficiency Virus. Study participants will be assigned to one of the 4 treatment groups and will receive a single dose of Budigalimab or placebo subcutaneous (SC) and intravenous (IV). Around 32 participants 18-65 years of age living with Human Immunodeficiency Virus will be enrolled in the study in approximately 9 sites worldwide.

Each participant will receive single dose of SC and IV Budigalimab and/or Placebo on day 1 and will be followed for 24 weeks.

Participants will attend weekly to every two and every four weeks visits during the study at a hospital. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects. There may be higher treatment burden for participants in this trial.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Human Immunodeficiency Virus (HIV) Acquired Immunodeficiency Syndrome Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Urogenital Diseases Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Ponce Medical School Foundation /ID# 224230, Ponce, Puerto Rico

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Condition of generally good health, body mass index ≥ 18.0 to < 35.0 kg/m2.
  • Laboratory values must meet acceptable criteria.
  • Human Immunodeficiency Virus (HIV-1) infected on antiretroviral therapy (ART) for at least 12 months prior to screening and on current ART regimen for at least 8 weeks prior to screening.
  • CD4 cell count ≥ 450 cells/μL at Screening and during the 12 months prior to Screening.
  • Plasma HIV-1 RNA below the lower limit of quantification at Screening and at least 6 months prior to Screening.
  • Participants agreeing to use an effective barrier method of protection (male and/or female condom) during sexual activity from Study Day 1 through last study visit for the purposes of prevention of HIV transmission.

Exclusion criteria

  • Participants with signs/symptoms associated with SARS-CoV-2 infection OR Current SARS-CoV-2 infection by any viral nucleic acid test completed within 7 days prior to the Day 1 dose.
  • Participants having history or ongoing diagnosis of acquired immunodeficiency syndrome (AIDS)-defining illness.
  • Participants having history of or active immunodeficiency (other than HIV).
  • Participants having active autoimmune disease or history of autoimmune disease that has required systemic treatment.
  • Prior therapy/exposure to budigalimab or any other immune checkpoint inhibitor [e.g., anti-programmed cell death protein 1(PD-1), anti-PD-L1, anti-PD-L2, anti-CTLA4].
  • Participants having clinically significant medical disorders that might expose the subjects to undue risk of harm, confound study outcomes, or prevent the subject from completing the study.
  • Participants having active or suspected malignancy or history of malignancy (other than basal cell skin cancer or cervical carcinoma in situ) in the past 5 years.
  • Participants with history of or active tuberculosis (TB) at screening.
  • Participants having known psychiatric or substance abuse disorders that would interfere with adherence to study requirements.
  • Participants who have received immunomodulatory or immunosuppressive (including IV/orally administered [PO] steroids at any dose, but excluding steroids that are inhaled, topical or via local injection) therapy within 24 weeks prior to the first dose of study drug.

Treatment and study plan

Budigalimab

Drug

Subcutaneous (SC)

Other names: ABBV-181

Placebo

Drug

Subcutaneous (SC)

Primary outcomes

  1. Number of Participants Experiencing Study Drug-Related Grade 3 or Higher Adverse Events (AEs)

    Time frame: Up to approximately 24 weeks

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of the study drug as either having a reasonable possibility or no reasonable possibility. AEs are given a grade from 1-5 with Grade 3 being severe but not life-threatening and requiring hospitalization, Grade 4 being life-threatening requiring immediate intervention and Grade 5 being death related to an AE.

  2. Number of Participants With Study Drug-Related Immune-Related Adverse Events (IRAE)

    Time frame: Up to approximately 24 weeks

    Assessed using the American Society of Clinical Oncology (ASCO) IRAE management guidelines [which utilizes the National Institutes of Health (NIH) Common Terminology Criteria for Adverse Events (CTCAE) grading scale] but modified, as applicable, according to the NIH Division of AIDS (DAIDS) (v2.1) AE grading scale.

  3. Maximum Serum Concentration (Cmax)

    Time frame: Up to approximately 24 weeks

    Maximum Serum Concentration (Cmax) of Budigalimab.

  4. Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Up to approximately 24 weeks

    Time to Maximum Observed Plasma Concentration (Tmax) of Budigalimab.

  5. Area Under the Plasma Concentration-time Curve (AUC) of Budigalimab in Plasma

    Time frame: Up to approximately 24 weeks

    Area Under the Plasma Concentration-time Curve (AUC).

  6. Terminal Phase Elimination Half-life (t1/2) of Budigalimab in Plasma

    Time frame: Up to approximately 24 weeks.

    Terminal phase elimination half-life (t1/2)

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-controlled Single-Dose Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Administration of Budigalimab in Adult People Living With HIV-1 (PLWH)

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Mar 16, 2021
Registry last updated
Oct 17, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.